These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 6263637)
1. The irreversible narcotic antagonistic and reversible agonistic properties of the fumaramate methyl ester derivative of naltrexone. Takemori AE; Larson DL; Portoghese PS Eur J Pharmacol; 1981 Apr; 70(4):445-51. PubMed ID: 6263637 [TBL] [Abstract][Full Text] [Related]
2. Activity of mu- and delta-selective opioid agonists in the guinea pig ileum preparation: differentiation into peptide and nonpeptide classes with beta-funaltrexamine. Ward SJ; LoPresti D; James DW J Pharmacol Exp Ther; 1986 Aug; 238(2):625-31. PubMed ID: 3016244 [TBL] [Abstract][Full Text] [Related]
3. Importance of C-6 chirality in conferring irreversible opioid antagonism to naltrexone-derived affinity labels. Sayre LM; Larson DL; Fries DS; Takemori AE; Portoghese PS J Med Chem; 1983 Sep; 26(9):1229-35. PubMed ID: 6310111 [TBL] [Abstract][Full Text] [Related]
4. Determination of the receptor selectivity of opioid agonists in the guinea-pig ileum and mouse vas deferens by use of beta-funaltrexamine. Hayes AG; Sheehan MJ; Tyers MB Br J Pharmacol; 1985 Dec; 86(4):899-904. PubMed ID: 3000501 [TBL] [Abstract][Full Text] [Related]
5. Irreversible opiate agonists and antagonists. II. Evidence against a bivalent mechanism of action for opiate azines and diacylhydrazones. Hahn EF; Nishimura S; Goodman RR; Pasternak GW J Pharmacol Exp Ther; 1985 Dec; 235(3):839-45. PubMed ID: 2416909 [TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of naltrexone-derived affinity labels with nonequilibrium opioid agonist and antagonist activities. Evidence for the existence of different mu receptor subtypes in different tissues. Sayre LM; Larson DL; Takemori AE; Portoghese PS J Med Chem; 1984 Oct; 27(10):1325-35. PubMed ID: 6090663 [TBL] [Abstract][Full Text] [Related]
7. Comparative antagonism by naltrexone and naloxone of mu, kappa, and delta agonists. Takemori AE; Portoghese PS Eur J Pharmacol; 1984 Sep; 104(1-2):101-4. PubMed ID: 6094203 [TBL] [Abstract][Full Text] [Related]
9. Effect of beta-FNA on opiate delta receptor binding. Rothman RB; Schumacher UK; Pert CB J Neurochem; 1984 Oct; 43(4):1197-200. PubMed ID: 6088697 [TBL] [Abstract][Full Text] [Related]
10. Application of an irreversible opiate antagonist (beta-FNA, beta-funal-trexamine) to demonstrate dynorphin selectivity for K-opioid sites. Huidobro-Toro JP; Yoshimura K; Way EL Life Sci; 1982 Nov; 31(22):2409-16. PubMed ID: 6130451 [TBL] [Abstract][Full Text] [Related]
11. The structure-action relationship and kinetics of some naloxone and naltrexone derivatives. Vizi ES; Foldes FF; Rich J; Knoll J Pharmacology; 1976; 14(1):76-85. PubMed ID: 959310 [TBL] [Abstract][Full Text] [Related]
12. Diastereomeric 6-desoxy-6-spiro-alpha-methylene-gamma-butyrolactone derivatives of naltrexone and oxymorphone. Selective irreversible inhibition of naltrexone binding in an opioid receptor preparation by a conformationally restricted michael acceptor ligand. Koolpe GA; Nelson WL; Gioannini TL; Angel L; Simon EJ J Med Chem; 1984 Dec; 27(12):1718-23. PubMed ID: 6209395 [TBL] [Abstract][Full Text] [Related]
13. A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activities. Portoghese PS; Larson DL; Sayre LM; Fries DS; Takemori AE J Med Chem; 1980 Mar; 23(3):233-4. PubMed ID: 6245210 [No Abstract] [Full Text] [Related]